Metronidazole and Rifampin — Competitive Intelligence Brief

Metronidazole and Rifampin (Metronidazole and Rifampin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

phase 3 Antibiotic combination Bacterial DNA (metronidazole); bacterial RNA polymerase (rifampin) Infectious Disease Small molecule

Target snapshot

Metronidazole and Rifampin (Metronidazole and Rifampin) — McMaster University. Metronidazole and rifampin are a combination of an antibiotic that disrupts bacterial DNA and an antibiotic that inhibits bacterial RNA polymerase, used together to treat infections resistant to single-agent therapy.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metronidazole and Rifampin TARGET	Metronidazole and Rifampin	McMaster University	phase 3	Antibiotic combination	Bacterial DNA (metronidazole); bacterial RNA polymerase (rifampin)
Standard bismuth quadruple	Standard bismuth quadruple	Xijing Hospital of Digestive Diseases	marketed	Antibiotic combination therapy / Bismuth-based anti-ulcer agent	Helicobacter pylori (bacterial pathogen)
Cefazolin and Metronidazole.	Cefazolin and Metronidazole.	The University of Texas Health Science Center, Houston	marketed	Beta-lactam antibiotic and nitroimidazole antibiotic combination	Penicillin-binding proteins (cefazolin); anaerobic bacterial DNA (metronidazole)
Vonoprazan+amoxicillin 7 days	Vonoprazan+amoxicillin 7 days	Xijing Hospital of Digestive Diseases	marketed	Potassium-competitive acid blocker + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Ceftazidime-avibactam + Colistin/Polymyxin B	Ceftazidime-avibactam + Colistin/Polymyxin B	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination	Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids
metronidazole and azithromycin	metronidazole and azithromycin	University of Alabama at Birmingham	marketed	Antibiotic combination	Bacterial DNA (metronidazole); bacterial 50S ribosome (azithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class